<span style="color: #222222;">Bharat Biotech has said that its nasal vaccine against Covid-19, iNCOVACC, would be available to the public from the fourth week of January. The Hyderabad-based biotechnology company said that the vaccine will cost 800 rupees for private markets and 325 rupees for governments.<br />''<br />''Bharat Biotech's INCOVACC is the world's first intranasal Covid vaccine to receive approval for the primary 2-dose schedule as well as a heterologous booster dose. The nasal vaccine will be rolled out as a booster dose for those above 18 years of age. iNCOVACC has been developed by Bharat Biotech in partnership with America's Washington University.&nbsp;</span><br />
News On AIR | December 28, 2022 1:43 PM
India's nasal vaccine against Covid-19 to be rolled out in January as booster dose for citizens aged 18 plus